+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Sequencing Reagents Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

  • PDF Icon


  • 117 Pages
  • January 2022
  • Region: Global
  • Mordor Intelligence
  • ID: 5119898

The Sequencing Reagents Market is expected to register a CAGR of 7.5% during the forecast period. This is attributing to increasing demand for third-generation sequencing, decreasing costs for genetic sequencing, and increasing R&D expenditure on genomic research. In addition, developments in sequencing technologies to provide high yield data for large scale genomic research and availability of new commercial reagents kits for specific sequencing technologies will also promote the growth of the sequencing reagents market. Nanopore and single-molecule real-time sequencing are some of the novel technologies, with its cost-effective and efficient preparation of sequencing the DNA results in adoption by researchers to sequence the genome in a short time and less cost. Moreover, the cost of genetic sequencing has been falling from USD 10-15 million per genome in 2001 to USD 1,200 per genome in 2017. Thus, the declining cost of genetic sequencing will boost the growth sequencing technologies, and which further drive the use of sequencing reagents. Furthermore, favorable government initiatives and increasing funding of private and public entities will also trigger the growth of sequencing technologies and propel the demand for sequencing reagents in the forecasted period.

Key Market Trends

Next Generation Sequencing (NGS) is Estimated to Witness a Healthy Growth in Future.

Next-generation sequencing (NGS) is estimated to witness a healthy growth in the future attributed to increasing adoption of several applications such as molecular pathology, molecular diagnostics, and other clinical research applications. The all in one and deep sequencing approach offered by NGS will minimize the time required to identify the root of the condition and helps in determining novel or rare variants. Moreover, the use of next-generation sequencing technologies in personalized medicines, companion diagnostic and in-vitro diagnostics led to high adoption compared to others and promotes the segment growth.

In Addition, As per Pharmaceutical Research & Manufacturer of America, biopharmaceutical research & development expenditure has been rising up from past years leading to drive the sequencing reagents market in the forecasted period.

North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period

North America is expected to hold a significant market share in the global Sequencing Reagents Market due to the rising prevalence of chronic diseases, the presence of a large number of pharmaceutical companies, growing research and development expenditure, rising awareness, product launches, and technological advancements. The United States owns the largest share of Sequencing Reagents Market in the North America region Furthermore, increasing adoption of novel sequencing technologies, well-established infrastructure, and increasing healthcare expenditure are also expected to fuel the Sequencing Reagents Market in this region.

Competitive Landscape

The Sequencing Reagents Market is moderately competitive and consists of several major players. Some of the companies which are currently dominating the market are F. Hoffmann-La Roche AG, Illumina, Inc, Thermo Fisher Scientific, Oxford Nanopore Technologies, Agilent Technologies, Inc., BGI, Bioline, Qiagen, Takara Bio Inc., and Fluidigm Corporation.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

This product will be delivered within 2 business days.

Table of Contents

1.1 Study Assumptions
1.2 Scope of the Study
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Demand for Third Generation Sequencing
4.2.2 Decreasing Costs for Genetic Sequencing
4.2.3 Increasing R&D Expenditure
4.3 Market Restraints
4.3.1 Limited Reimbursement Policy and Regulation for NGS
4.3.2 Ethical and Social Issues Associated with Sequencing
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5.1 By Type
5.1.1 Template Kits
5.1.2 Library Kits
5.1.3 Control Kits
5.1.4 Sequencing Kits
5.1.5 Others
5.2 By Technology
5.2.1 Next Generation Sequencing
5.2.2 Sanger Sequencing
5.2.3 Third Generation Sequencing
5.3 By Application
5.3.1 Clinical Investigation
5.3.2 Oncology
5.3.3 Forensics & Agrigenomics
5.3.4 Others
5.4 Geography
5.4.1 North America United States Canada Mexico
5.4.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.4.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.4.4 Middle-East and Africa GCC South Africa Rest of Middle-East and Africa
5.4.5 South America Brazil Argentina Rest of South America
6.1 Company Profiles
6.1.1 F. Hoffmann-La Roche AG
6.1.2 Illumina, Inc
6.1.3 Thermo Fisher Scientific
6.1.4 Oxford Nanopore Technologies
6.1.5 Agilent Technologies, Inc.
6.1.6 BGI
6.1.7 Bioline
6.1.8 Qiagen
6.1.9 Takara Bio Inc.
6.1.10 Fluidigm Corporation

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • F. Hoffmann-La Roche AG
  • Illumina, Inc
  • Thermo Fisher Scientific
  • Oxford Nanopore Technologies
  • Agilent Technologies, Inc.
  • BGI
  • Bioline
  • Qiagen
  • Takara Bio Inc.
  • Fluidigm Corporation